Contract

Senior Manager

Capital Contracting and Deal Desk

Posted on 8/1/2025

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

Texas, USA

Remote

Must be able to travel up to 75% of the time, with typical work-related travel assignments ranging from 1-5 days.

Category
Sales & Account Management (2)
,
Required Skills
Lead Generation
Customer Service
Requirements
  • Bachelor’s degree in business, marketing, sales, or a related field. Master’s degree is preferred.
  • 8+ years of surgical sales experience, preferably in a strategic sales, training, or sales leadership
  • Proven track record of meeting or exceeding sales targets and driving growth in competitive markets.
  • 5+ Years of leadership in Capital Sales
  • 5+ years experience in financing/ contracting agreements
Responsibilities
  • Develop improved strategies that allow for the achievement of our strategic and business plan goals related to contracted sales growth, price erosion, gross profit increase, and share gains across various strategic channels (Tiers, GPOs, RPCs, Govt, ASC’s, etc.)
  • Work with finance to determine banking/cash support for capital programs.
  • Partner across multiple cross-functional business partners including finance marketing, commercial operations, legal, health care compliance, sales, key account management, offer development, contract management, and customer service to create E2E and E2B commercial program models that can be successfully and compliantly implemented with Customers
  • Advance existing models for how Customers can acquire capital and enabling technology offerings (inclusive of software and data products) and value-added solutions that maximize long-term customer commitment and partnership
  • Help Support, develop and implement comprehensive sales strategies, promotions, and incentives targeting key surgeons, new markets, and growth opportunities
  • Engage Field Selling Org on Sales Funnel adoption; lead generation, qualifying, presenting, training, closing
  • Assist field sales leaders, sales agents and the field sales organization in capital sales acquisition by leveraging key financial programs and deal creation.
  • Consistently monitor industry developments, competitor activities, and consumer behavior to understand evolving market dynamics that inform strategic contracting decisions
  • Staff all trade shows and regional or local meetings as determined by the leadership team. This includes labs and other product training events.
  • Work with the Commercial Education team to assist in the training and education of new Sales Representatives. This training would be related to contracting, capital and enabling technology sales related strategies
  • Support Medical Education team to assist and training and education of surgeons for Enabling Technology contracting and deal options for acquisition into their site of care
  • Support ASC Strategy with creative deal offerings for capital equipment
Desired Qualifications
  • Strong strategic thinking, problem-solving, and decision-making skills.
  • Excellent negotiation, communication, and interpersonal skills.
  • Proven ability to build relationships with high-level stakeholders and close complex deals.
  • Analytical mindset with the ability to interpret sales data and market trends to make informed decisions.
  • Proficiency in CRM systems and other sales management software.
  • Supervisory Skills - ability to direct and manage a team of direct and indirect reports.
  • Proficiency in Microsoft Office Suite (Excel, PowerPoint, Word)
  • Analytical, Entrepreneurial, Cross-functional collaboration, Process & Continuous improvement
  • Ability to manage multiple products in a fact paced environment
  • Working knowledge of online sales tools and social networks (i.e. LinkedIn)

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment achieves 10% organic growth led by double-digit shoulder gains.
  • ARVIS robot deployment starts with South Africa procedure, adoption expands through 2026.
  • BTIG initiates Buy rating with $41 target on new launches in hips and knees.

What critics are saying

  • $1.18B goodwill impairment from LimaCorporate overpayment erodes R&D capital now.
  • Stryker Mako captures 60% US robotic shoulder procedures, blocks ARVIS adoption by 2027.
  • Zimmer Biomet Persona IQ steals Nebula conversions, slows recon growth by mid-2027.

What makes ENOVIS unique

  • Enovis leverages Enovis Growth Excellence system for continuous operational improvements.
  • Enovis offers ARVIS shoulder robot and Augmented Reverse Glenoid System for extremities.
  • Enovis integrates LimaCorporate acquisition to expand reconstructive implant portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.

INACTIVE